We therefore collected 56 CLL cases with MYD88 mutations, and assessed their clinical, morphologic, immunophenotypic features, fluorescence in situ hybridization (FISH), and next generation sequencing (NGS) findings and correlated with the clinical outcomes. The gene discussed is MYD88; the disease is B-cell chronic lymphocytic leukemia.